



The PANZYGA Co-Pay Programs

panzyga[®]

Immune Globulin
Intravenous (Human) - ifas
10% Liquid Preparation

Eligible patients
may pay as little as

\$0 for PANZYGA*

- **Patients must have commercial insurance to be eligible**
- **Patients are not eligible if they are enrolled in a state or federally funded insurance program**

*The PANZYGA Co-Pay Program provides eligible, commercially insured patients assistance of up to **[\$12,500]** per calendar year or the cost of patient co-pay in a 12-month period, whichever is less. The value of admin co-pay support is limited to a maximum of **[\$1,500]** for PANZYGA per calendar year or the cost of patient co-pay in a 12-month period, whichever is less. No membership fees. Federal and state health care beneficiaries are not eligible. Private insurance only. The PANZYGA Co-Pay Program is good only in the U.S. and Puerto Rico. The PANZYGA Admin Support Co-Pay Program is not valid for Massachusetts or Rhode Island residents. Additional terms and conditions can be found at <https://pfizeriguide.com>



INDICATIONS AND USAGE

PANZYGA (Immune Globulin Intravenous [Human] – ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older, chronic immune thrombocytopenia (cITP) in adults and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.

PANZYGA is a liquid medicine for infusion that contains immunoglobulin G (IgG), which are proteins that help fight infection. It is made from human plasma that is donated by healthy people and contains antibodies. For patients with PI, PANZYGA helps replace the missing antibodies in the body. For patients with cITP, PANZYGA helps the body produce more platelets (the blood cells that help blood clot) to control or prevent bleeding. For patients with CIDP, PANZYGA may help improve mobility and hand strength.

PANZYGA is given into a vein (intravenously) in a hospital, infusion center, doctor's office, or at home by a trained healthcare provider (HCP).

SELECT IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE

See full prescribing information for complete BOXED WARNING

- **Thrombosis may occur with immune globulin intravenous (IGIV) products, including PANZYGA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.**
- **Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. PANZYGA does not contain sucrose.**
- **For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer PANZYGA at the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.**

Please see Important Safety Information throughout and click [here](#) for full Prescribing Information, including complete BOXED WARNING.

The PANZYGA Co-Pay Programs are available through participating specialty infusion pharmacies



What is PANZYGA?

PANZYGA is a liquid medicine for infusion that contains immunoglobulin G (IgG), which is a protein that helps fight infection. PANZYGA is used to treat patients 2 years of age and older with primary immunodeficiency (PI), adults with chronic immune thrombocytopenia (cITP), and adults with chronic inflammatory demyelinating polyneuropathy (CIDP).



What does the Drug Co-Pay provide?

Eligible, commercially insured patients may pay as little as \$0 for PANZYGA and may receive a maximum benefit of **[\$12,500]** per year or the cost of the patient's co-pay in a 12-month period (whichever is less) for claims received by the program. Terms and conditions/eligibility requirements apply. (See terms and conditions.)



What is the Admin Support Co-Pay Program

In addition, eligible patients can receive up to **[\$1,500]** per calendar year for costs associated with administering therapy—including home infusions, administration services, and supplies/equipment. (See terms and conditions.)



What are the eligibility requirements for the PANZYGA Co-Pay Programs?

- Patients must be 2 years or older to be eligible
 - Patients must have commercial insurance to be eligible
 - Patients are not eligible if they are enrolled in a state or federally funded insurance program
 - The PANZYGA Co-Pay Program is good only in the U.S. and Puerto Rico
 - The PANZYGA Admin Support Co-Pay Program is not valid for Massachusetts or Rhode Island residents
- (See terms and conditions.)

**ENROLL
NOW**

**Contact your specialty infusion pharmacy or
Pfizer IGuide™ at www.pfizeriguide.com**

SELECT IMPORTANT SAFETY INFORMATION (continued)

Do not use PANZYGA if you:

- Have had a severe allergic reaction to immune globulin or other blood products
- Have a condition called selective (or severe) immunoglobulin A (IgA) deficiency, with antibodies against IgA and a history of hypersensitivity

What should I know before taking PANZYGA?

- PANZYGA can make vaccines (like measles/mumps/rubella or chickenpox vaccines) work less effectively for you. Before you get any vaccines, tell your healthcare provider that you take PANZYGA
- Decreased kidney function and kidney function failure can occur
- Severe headache, drowsiness, fever, painful eye movements, or nausea and vomiting can occur
- Elevated blood pressure can occur particularly in patients who have a history of hypertension (high blood pressure)
- If you are elderly, with heart or kidney problems, discuss with your healthcare provider prior to initiating treatment with PANZYGA
- PANZYGA is made from human blood and therefore may have a risk of transmitting infectious agents, including viruses and, theoretically, the variant Creutzfeldt-Jakob disease (CJD) and CJD agent. The production and manufacturing process reduces this risk, but the risk cannot be eliminated


TERMS AND CONDITIONS

By using the Panzyga Co-Pay Program you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

- Patients are not eligible to use the Panzyga Co-Pay Program card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
- Patient must have private insurance. Offer is not valid for cash-paying patients. The value of this co-pay card is limited to a maximum of **[\$12,500]** for Panzyga per calendar year or the cost of patient co-pay in a 12-month period, whichever is less. The value of the admin co-pay support is limited to a maximum of **[\$1,500]** for Panzyga per calendar year or the cost of patient co-pay in a 12-month period, whichever is less.
- This co-pay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
- You must deduct the value of this co-pay card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
- You are responsible for reporting use of the co-pay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
- You must be 2 years of age or older to redeem the Panzyga Co-Pay Program Card.
- This co-pay card is not valid where prohibited by law.
- The benefit under the co-pay card program is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
- Co-pay card cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator” or “maximizer” programs).
- Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the co-pay card program.
- **The Panzyga Co-Pay Program Card will be accepted only at participating pharmacies.**
- **If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.**
- **This co-pay card is not health insurance.**
- The Panzyga Co-Pay Program is good only in the U.S. and Puerto Rico. The Panzyga Admin Co-pay Support Program is not valid for Massachusetts or Rhode Island residents.
- The Panzyga Co-Pay Program Card are limited to 1 per person during this offering period and is not transferable.
- Co-pay card may not be redeemed more than once per 13 days per patient for Panzyga.
- No other purchase is necessary.
- No membership fee.
- Data related to your redemption of the co-pay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
- Pfizer reserves the right to rescind, revoke or amend this offer without notice.
- Offer expires **[12/31/2025]**.

For more information about the Panzyga Co-Pay Program call 1-866-293-5922. For more information about the Panzyga Co-Pay Program, write: Panzyga Co-Pay Program, PO Box 6875, Bridgewater, NJ 08807.

Please see Important Safety Information throughout and click [here](#) for full Prescribing Information, including complete BOXED WARNING.



mypanzyga[™]

**is a program for patients
and their caregivers.**

**Sign up at PanzygaInfo.com for
additional information to help you
understand more about PANZYGA and to
receive educational and patient support.**



Not actual patient

SELECT IMPORTANT SAFETY INFORMATION (continued)

PANZYGA can cause serious side effects. If any of the following problems occur after starting PANZYGA, stop the infusion immediately and contact your HCP or call emergency services:

- Hives, swelling in the mouth or throat, itching, trouble breathing, wheezing, fainting, or dizziness. These could be signs of a serious allergic reaction
- Bad headache with nausea, vomiting, stiff neck, fever, drowsiness, painful eye movements, and sensitivity to light. These could be signs of irritation and swelling of the lining around your brain
- Reduced urination, sudden weight gain, or swelling in your legs. These could be signs of a kidney problem (decreased kidney function or kidney failure)
- Pain, swelling, warmth, redness, or a lump in your legs or arms. These could be signs of a blood clot, which could happen in the heart, brain, lungs, or elsewhere in the body
- Brown or red urine, swelling, fatigue, fast heart rate, difficulty breathing, or yellow skin or eyes. These could be signs of a liver or blood problem
- Chest pain or trouble breathing, or blue lips or extremities. These could be signs of a serious heart or lung problem
- Fever over 100°F. This could be a sign of an infection
- Headache, fatigue or confusion, vision problem, chest pain, difficulty breathing, irregular heartbeat, or pounding in your chest, neck, or ears. These could be signs of high blood pressure

Ask your HCP whether you should have rescue medications available, such as antihistamines or epinephrine.

What are the possible or reasonably likely side effects for PANZYGA?

The most common side effects that may occur with PANZYGA are:

- | | | | | |
|------------|----------------------------|--------------|------------------|----------|
| • Headache | • Fever | • Dermatitis | • Abdominal pain | • Anemia |
| • Nausea | • Increased blood pressure | • Fatigue | • Dizziness | |

These are not all the possible side effects. Talk to your HCP about any side effect that bothers you or that does not go away. Tell your HCP if you are pregnant, or plan to become pregnant, or if you are nursing.

Please see Important Safety Information throughout and click [here](#) for full Prescribing Information, including complete BOXED WARNING.



Manufactured by Octapharma Pharmazeutika Produktionsges m.b.H.
Distributed by Pfizer Labs, Division of Pfizer Inc.